BiotechTube
Home/Teva/Eli (Evan) Lippman
E(

Eli (Evan) Lippman

Executive Vice President, Business Development

Teva

Therapeutic Areas

NeuroscienceImmunology

Teva Pipeline

DrugIndicationPhase
Biosimilar to Xgeva® (denosumab)Oncology (bone metastases)Approved/Under Review
Biosimilar to Prolia® (denosumab)OsteoporosisApproved/Under Review
Biosimilar to Simponi® (golimumab)Inflammatory DiseasesUnder Regulatory Review
Biosimilar to Xolair® (omalizumab)Asthma, Chronic Spontaneous UrticariaFiled
TEV-'574 (or similar)Ulcerative Colitis, Crohn’s DiseasePhase 3
Asthma CandidateAsthmaPhase 3
Schizophrenia CandidateSchizophreniaPhase 3
MSA CandidateMultiple System AtrophyPhase 2

Leadership Team at Teva

RF
Richard Francis
President and Chief Executive Officer
ED
Eric Drape
Executive Vice President and Chief Financial Officer
HF
Hafrun Fridriksdottir
Executive Vice President, Global R&D
SD
Sven Dethlefs
Executive Vice President, Global Marketing and Access
View full Teva profile